Advancing Medicine Is In Daniel MacArthur’s DNA

When genomic scientist Daniel MacArthur had the opportunity to set up a new Centre for Population Genomics in Australia in 2019, he jumped at the chance to return home after 12 years living overseas.
Daniel MacArthur with Melbourne scientist and assistant professor Misty Jenkins. Both will be speaking at the Sohn Hearts & Minds conference in Sydney.

Glenda Korporaal

Advancing Medicine Is In Daniel MacArthur’s DNA

November 15, 2023
When genomic scientist Daniel MacArthur had the opportunity to set up a new Centre for Population Genomics in Australia in 2019, he jumped at the chance to return home after 12 years living overseas.
Read Transcript

When genomic scientist Daniel MacArthur had the opportunity to set up a new Centre for Population Genomics in Australia in 2019, he jumped at the chance to return home after 12 years living overseas.

Based in Boston as co-director of the Medical and Population Genomics Program at the Broad Institute for Mendelian Genomics at MIT and Harvard, his work in the US had involved using new genomic technologies to help predict and diagnose diseases.

It included overseeing a team that built one of the largest genetic data bases ever assembled, collecting data from more than 140,000 people.

MacArthur saw the new centre – a joint initiative of the Garvan Institute in Sydney and the Murdoch Children’s Institute in Melbourne – as the chance to bring his years of expertise in genomic medicine back to Australia.

“The centre’s focus is applying a lot of the lessons we had learned in the early days in building the field of genomic medicine, particularly in places like the US and the UK, and applying it in the context of the Australian community,” MacArthur says.

MacArthur will outline his ­vision for genomic medicine in Australia at the Sohn Hearts & Mind Conference in Sydney on Friday.

The conference, which features top fund managers from Australia and around the world giving their best stock tips, has raised $60m for medical research in Australia since it began in 2016.

This is the first year that The Centre for Population Genomics, which has been funded from a combination of government grants and philanthropy, will receive funding from the conference.

MacArthur says his aim at the conference will be to explain the potential of the developing field of genomic medicine in Australia, adding that it is “an exciting time for the field”.

While genetics involves the study of how a person’s genes can cause a disease or an illness, the newer field of genomics involves the study of all of a person’s genes – the genome – looking at how the combination of genetic factors and environment can cause disease.

“All conditions, including the big killers like heart disease and cancer, have a contribution from both our DNA and the environment,” MacArthur says.

“If we can better understand the DNA component, it makes it a lot easier for us to identify the ­people who are most at risk of those conditions and give them the information they might need to make lifestyle changes, and also to think about how we might be able to develop therapies which could reduce the risk of those ­conditions.”

MacArthur’s work has included understanding the basis of certain rare genetic disorders, which can cause diseases such as muscular dystrophy and which particularly affect children.

Working in Boston, he oversaw a program that sequenced and analysed genomic data from more than 10,000 people from families with rare diseases – work that contributed to the discovery of more than 100 new rare disease genes.

‘We can now think about making precise changes to someone’s DNA’

Daniel MacArthur, genomic scientist

But Australia’s racial mix – which includes many people from Asia, the Middle East and South Pacific – is very different to that in the European nations that have provided the basis for a lot of genomic medicine research to date.

“My driving purpose with the centre is thinking about ways we can make sure the benefit of new technologies is available to all Australians, regardless of their background,” MacArthur said.

“We are focused on working directly with communities to build up a better picture of the patterns of genetic variation that exist within the Australian community and use it to predict and build better tools for the diagnosis, prediction and treatment of ­disease.”

When MacArthur left Australia, in 2007, after completing his PhD in human genetics at the University of Sydney, there was little work being done in the field of genomics. “But since then, there has been a huge amount of work to build up the infrastructure and the approaches to it,” he says.

“The centre, is a partnership between two different institutions in Sydney and Melbourne, is a new approach to bringing together genetic information at a very large scale in a way which can benefit Australian communities, not just the ones that are already being studied in other places around the world.”

MacArthur is based in Sydney and oversees a team that has members in Sydney, Melbourne and New Zealand.

One of his goals is to build a ­genomic data base from about 10,000 people from specific groups in Australia, including people from the Pacific, Southeast Asia, the Middle East and East ­Africa, to help study diseases in those populations.

“More than a quarter of Australian citizens were born overseas and more than half have at least one parent born overseas,” he says. “It is essential we have a genetic resource which is fit for purpose in our own country, which captures the full spectrum of diversity which exists here.”

He says the study of genomic medicine is now taking off as a result of a combination of factors including a sharp drop in the cost of the technology involved.

“The first human genome, which took about 10 years to ­sequence by a team of scientists around the world, was released in 2003, and took about $3bn to generate,” he says. “These days we can sequence a genome for less than $1000. It takes a week and is more accurate than the genome we generated back in 2003.

“It is an almost unprecedented drop in the cost of the technology which allows us to think about ­applying genomics to so many people around the world and so many patients.”

Big advances in data science such as cloud computing and the broader availability of artificial intelligence have also allowed for much easier processing of huge amounts of data.

“These technologies are now the key factor in our ability to make sense of the data and use it to diagnose, predict and treat disease,” MacArthur says.

There have also been big advances in the drugs and therapeutics available to treat diseases.

“It means we can now think about making precise changes to someone’s DNA in ways which can help cure their condition, or even potentially prevent a condition that they might go on to develop in future,” MacArthur says.

The Australian is a media partner of Sohn Hearts & Minds. You can watch Prof Daniel MacArthur's presentation from the event here.

This article was originally posted by The Australian here.

Licensed by Copyright Agency. You must not copy this work without permission.

When genomic scientist Daniel MacArthur had the opportunity to set up a new Centre for Population Genomics in Australia in 2019, he jumped at the chance to return home after 12 years living overseas.

Based in Boston as co-director of the Medical and Population Genomics Program at the Broad Institute for Mendelian Genomics at MIT and Harvard, his work in the US had involved using new genomic technologies to help predict and diagnose diseases.

It included overseeing a team that built one of the largest genetic data bases ever assembled, collecting data from more than 140,000 people.

MacArthur saw the new centre – a joint initiative of the Garvan Institute in Sydney and the Murdoch Children’s Institute in Melbourne – as the chance to bring his years of expertise in genomic medicine back to Australia.

“The centre’s focus is applying a lot of the lessons we had learned in the early days in building the field of genomic medicine, particularly in places like the US and the UK, and applying it in the context of the Australian community,” MacArthur says.

MacArthur will outline his ­vision for genomic medicine in Australia at the Sohn Hearts & Mind Conference in Sydney on Friday.

The conference, which features top fund managers from Australia and around the world giving their best stock tips, has raised $60m for medical research in Australia since it began in 2016.

This is the first year that The Centre for Population Genomics, which has been funded from a combination of government grants and philanthropy, will receive funding from the conference.

MacArthur says his aim at the conference will be to explain the potential of the developing field of genomic medicine in Australia, adding that it is “an exciting time for the field”.

While genetics involves the study of how a person’s genes can cause a disease or an illness, the newer field of genomics involves the study of all of a person’s genes – the genome – looking at how the combination of genetic factors and environment can cause disease.

“All conditions, including the big killers like heart disease and cancer, have a contribution from both our DNA and the environment,” MacArthur says.

“If we can better understand the DNA component, it makes it a lot easier for us to identify the ­people who are most at risk of those conditions and give them the information they might need to make lifestyle changes, and also to think about how we might be able to develop therapies which could reduce the risk of those ­conditions.”

MacArthur’s work has included understanding the basis of certain rare genetic disorders, which can cause diseases such as muscular dystrophy and which particularly affect children.

Working in Boston, he oversaw a program that sequenced and analysed genomic data from more than 10,000 people from families with rare diseases – work that contributed to the discovery of more than 100 new rare disease genes.

‘We can now think about making precise changes to someone’s DNA’

Daniel MacArthur, genomic scientist

But Australia’s racial mix – which includes many people from Asia, the Middle East and South Pacific – is very different to that in the European nations that have provided the basis for a lot of genomic medicine research to date.

“My driving purpose with the centre is thinking about ways we can make sure the benefit of new technologies is available to all Australians, regardless of their background,” MacArthur said.

“We are focused on working directly with communities to build up a better picture of the patterns of genetic variation that exist within the Australian community and use it to predict and build better tools for the diagnosis, prediction and treatment of ­disease.”

When MacArthur left Australia, in 2007, after completing his PhD in human genetics at the University of Sydney, there was little work being done in the field of genomics. “But since then, there has been a huge amount of work to build up the infrastructure and the approaches to it,” he says.

“The centre, is a partnership between two different institutions in Sydney and Melbourne, is a new approach to bringing together genetic information at a very large scale in a way which can benefit Australian communities, not just the ones that are already being studied in other places around the world.”

MacArthur is based in Sydney and oversees a team that has members in Sydney, Melbourne and New Zealand.

One of his goals is to build a ­genomic data base from about 10,000 people from specific groups in Australia, including people from the Pacific, Southeast Asia, the Middle East and East ­Africa, to help study diseases in those populations.

“More than a quarter of Australian citizens were born overseas and more than half have at least one parent born overseas,” he says. “It is essential we have a genetic resource which is fit for purpose in our own country, which captures the full spectrum of diversity which exists here.”

He says the study of genomic medicine is now taking off as a result of a combination of factors including a sharp drop in the cost of the technology involved.

“The first human genome, which took about 10 years to ­sequence by a team of scientists around the world, was released in 2003, and took about $3bn to generate,” he says. “These days we can sequence a genome for less than $1000. It takes a week and is more accurate than the genome we generated back in 2003.

“It is an almost unprecedented drop in the cost of the technology which allows us to think about ­applying genomics to so many people around the world and so many patients.”

Big advances in data science such as cloud computing and the broader availability of artificial intelligence have also allowed for much easier processing of huge amounts of data.

“These technologies are now the key factor in our ability to make sense of the data and use it to diagnose, predict and treat disease,” MacArthur says.

There have also been big advances in the drugs and therapeutics available to treat diseases.

“It means we can now think about making precise changes to someone’s DNA in ways which can help cure their condition, or even potentially prevent a condition that they might go on to develop in future,” MacArthur says.

The Australian is a media partner of Sohn Hearts & Minds. You can watch Prof Daniel MacArthur's presentation from the event here.

This article was originally posted by The Australian here.

Licensed by Copyright Agency. You must not copy this work without permission.

Disclaimer: This material has been prepared by The Australian, published on Nov 15, 2023. HM1 is not responsible for the content of linked websites or content prepared by third party. The inclusion of these links and third-party content does not in any way imply any form of endorsement by HM1 of the products or services provided by persons or organisations who are responsible for the linked websites and third-party content. This information is for general information only and does not consider the objectives, financial situation or needs of any person. Before making an investment decision, you should read the relevant disclosure document (if appropriate) and seek professional advice to determine whether the investment and information is suitable for you.

facebook
linkedin
All
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Martin Hughes founder of UK-based Toscafund. Picture: Elke MeitzelMartin Hughes founder of UK-based Toscafund. Picture: Elke MeitzelMartin Hughes founder of UK-based Toscafund. Picture: Elke MeitzelMartin Hughes founder of UK-based Toscafund. Picture: Elke Meitzel
November 16, 2023

Hedge Fund Veteran Talks Lowest Moment In Toscafund’s 23-Year Run

Most hedge fund managers brag about their wins and shy away from their losses – Martin Hughes is not most hedge fund managers.

Read More
November 16, 2023

The ‘Armageddon Scenario’ Worrying The Future Fund CIO

Mr Samild shared his thoughts on the bond market – which underpins the returns of other assets – ahead of his appearance at Friday’s Sohn Hearts & Minds charity conference at the Sydney Opera House.

Read More
November 15, 2023

Ashish Swarup - Invest In Snacks, Let's Get That Bread | Aikya Investment Management

Ashish Swarup, Portfolio Manager and Investment Analyst of Aikya Investment Management joins Bryce and Ren to discuss emerging markets, and two stock deep dives.

Read More
Surging interest rates have delivered new investment opportunities for Wall Street hedge fund Third Point. Picture: Getty Images/AFPSurging interest rates have delivered new investment opportunities for Wall Street hedge fund Third Point. Picture: Getty Images/AFPSurging interest rates have delivered new investment opportunities for Wall Street hedge fund Third Point. Picture: Getty Images/AFPSurging interest rates have delivered new investment opportunities for Wall Street hedge fund Third Point. Picture: Getty Images/AFP
November 15, 2023

Daniel Loeb’s Wall St Hedge Fund Third Point Raises Bets On Corporate Credit Crunch

An “obsession” around balance sheet strength and debt is creating a new wave of investment bets for the influential Wall Street hedge fund run by Daniel Loeb.

Read More
November 13, 2023

Bond Bullish On Commodity Stocks, Uranium

Mining stocks are poised to rise amid tight supply for key commodities such as copper, nickel and uranium, says Terra Capital founder Jeremy Bond.

Read More
November 13, 2023

This Hedge Fund Manager Is Making A 100-Year Bet On Luxury

European leisure and luxury – a designer handbag, a last-minute flight to Monte Carlo, a stay in a five-star hotel – is where many choose to spend their hard-earned cash. For Sharif el Khazen, it’s where he makes it.

Read More
Munro partner and portfolio manager Kieran Moore says Nvidia will be critical in the expansion of accelerated computing. Picture: NCANewswire / Nicki ConnollyMunro partner and portfolio manager Kieran Moore says Nvidia will be critical in the expansion of accelerated computing. Picture: NCANewswire / Nicki ConnollyMunro partner and portfolio manager Kieran Moore says Nvidia will be critical in the expansion of accelerated computing. Picture: NCANewswire / Nicki ConnollyMunro partner and portfolio manager Kieran Moore says Nvidia will be critical in the expansion of accelerated computing. Picture: NCANewswire / Nicki Connolly
November 12, 2023

How Munro Will Pick Its Next Stock Winner

Munro partner and portfolio manager Kieran Moore must select a single company to pitch to an audience of industry heavyweights at the prestigious Sohn Hearts & Minds conference in Sydney.

Read More
Ray Dalio last month. His hedge fund has been under heightened scrutiny with the release of a tell-all book. Picture: BloombergRay Dalio last month. His hedge fund has been under heightened scrutiny with the release of a tell-all book. Picture: BloombergRay Dalio last month. His hedge fund has been under heightened scrutiny with the release of a tell-all book. Picture: BloombergRay Dalio last month. His hedge fund has been under heightened scrutiny with the release of a tell-all book. Picture: Bloomberg
November 12, 2023

The Australian At The Centre Of Dalio’s Bridgewater – Who Loves It

The culture at Ray Dalio’s massive hedge fund has been a source of intrigue, and with a new book, controversy. Atul Lele says it’s made him a better investor.

Read More
Sheila Patel has had an extraordinary career across Goldman Sachs and now the VC sector. Picture: Dominic LorrimerSheila Patel has had an extraordinary career across Goldman Sachs and now the VC sector. Picture: Dominic LorrimerSheila Patel has had an extraordinary career across Goldman Sachs and now the VC sector. Picture: Dominic LorrimerSheila Patel has had an extraordinary career across Goldman Sachs and now the VC sector. Picture: Dominic Lorrimer
November 10, 2023

Meet The Goldman Sachs Legend Shaking Up Venture Capital

Sheila Patel says it was time for the venture capital sector to “grow up” and higher rates will help do that job. VC firms need to think differently about how they invest.

Read More
November 8, 2023

Tom Naughton - There's Money In Mi Goreng | Prusik Investment

Tom Naughton is Managing Partner and CIO at Prusik Investment. In this episode, he chats to Equity Mates ahead of his appearance at the 2023 Sohn Hearts and Minds Conference.

Read More
November 6, 2023

Why Chris Kourtis just bought CSL and ResMed

A true contrarian investor, Chris Kourtis can find himself sounding a lot like a bull when in the company of bears, and there’s a lot to be bearish about at the moment.

Read More
Jun Bei Liu being coached by Jonathan Pease. Picture: Renee Nowytarger.Jun Bei Liu being coached by Jonathan Pease. Picture: Renee Nowytarger.Jun Bei Liu being coached by Jonathan Pease. Picture: Renee Nowytarger.Jun Bei Liu being coached by Jonathan Pease. Picture: Renee Nowytarger.
November 5, 2023

Five Secrets To Delivering The Perfect Pitch

Australia’s best stock pickers have just eight minutes to convince the country’s top money managers they have found an investment gem that the market has overlooked.

Read More
Picture: Solomon Lew & David ParadicePicture: Solomon Lew & David ParadicePicture: Solomon Lew & David ParadicePicture: Solomon Lew & David Paradice
November 3, 2023

Paradice and Lew on their love of medical research – and Greece

Solomon Lew, the billionaire retailer, has known David Paradice, the high-profile fund managers, for years. Beyond investing, they share a common interest in medical research – and holidaying in Greece.

Read More
November 2, 2023

Meet the 2023 Conference Managers

Following a rigorous global search, the Conference Fund Manager Selection Committee is pleased to share ten new managers for 2023.

Read More
Daniel Loeb oversees $US11.7 billion ($18.5 billion) at New York-based Third Point. Picture: BloombergDaniel Loeb oversees $US11.7 billion ($18.5 billion) at New York-based Third Point. Picture: BloombergDaniel Loeb oversees $US11.7 billion ($18.5 billion) at New York-based Third Point. Picture: BloombergDaniel Loeb oversees $US11.7 billion ($18.5 billion) at New York-based Third Point. Picture: Bloomberg
October 23, 2023

Dan Loeb to headline Sohn Hearts & Minds

Famed hedge fund manager Dan Loeb has been named as one of the headline acts for next month’s Sohn Hearts & Minds philanthropic investment conference to be held in Sydney.

Read More